Sars 2 Antibody Tes

Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease sactivity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps.

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), with an N-terminal MBP-tag, expressed in an E. coli expression system, MW=77.5 kDa.

Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Description: A polyclonal antibody against TES. Recognizes TES from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB

Description: A polyclonal antibody against TES. Recognizes TES from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:5000, IHC:1:500-1:1000, IF:1:200-1:500

Description: Rabbit polyclonal TES antibody

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.

The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.